Xenetic Biosciences, Inc.
XBIO
Rank in Stocks
#30866
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily... Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Share Price
$1.80
Last synced: 2026-11-09
Market Cap
$4.21M
Change (1 day)
-3.91%
Change (1 year)
-34.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xenetic Biosciences, Inc. (XBIO)
Category
Healthcare
Operating Margin for Xenetic Biosciences, Inc. (XBIO)
Operating Margin as of November 2026 TTM: -81.01%
According to Xenetic Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -81.01%. At the end of 2025 the company had an operating margin of -95.23%.
Operating Margin history for Xenetic Biosciences, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -81.01% | -14.93% |
| 2025 | -95.23% | -43.37% |
| 2024 | -168.16% | -5.42% |
| 2023 | -177.79% | -54.83% |
| 2022 | -393.57% | -20.51% |
| 2021 | -495.12% | -84.48% |
| 2020 | -3,189.82% | -95.78% |
| 2019 | -75,511.71% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -47.05% | -97.02% |
| 2016 | -1,581.02% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -861.35% | -60.14% |
| 2012 | -2,160.83% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.48% |
US
|
|
| -149.01% | -98.16% |
US
|
|
| 25.57% | -100.32% |
AU
|
|
| 31.23% | -100.39% |
BE
|
|
| 29.35% | -100.36% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Xenetic Biosciences, Inc.'s operating margin
What is Xenetic Biosciences, Inc.'s operating margin?
Xenetic Biosciences, Inc.'s operating margin is -81.01%, as of Nov 2026.
What was Xenetic Biosciences, Inc.'s operating margin in 2025?
In 2025, Xenetic Biosciences, Inc.'s operating margin was -95.23%, compared with -168.16% in 2024.
How has Xenetic Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Xenetic Biosciences, Inc.'s operating margin was highest in 2025 (-95.23%) and lowest in 2020 (-3,189.82%).
How does Xenetic Biosciences, Inc.'s operating margin compare with similar companies?
Xenetic Biosciences, Inc.'s operating margin (-81.01%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.